Company Information


Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal and multi-specific antibodies that modulate targets of interest, as well as allogeneic cell therapies through its subsidiary MiNK therapeutics. In addition, the Company’s cancer vaccine program includes proprietary individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory antibodies, cell therapies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with BMS, Gilead, Merck and Incyte to discover and develop multiple checkpoint antibodies.

Press Releases
Oct 25, 2021
Conference Call on Tuesday, November 9, 2021, at 8:30 a.m. ET LEXINGTON, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to
Oct 22, 2021
Company voluntarily withdraws BLA at FDA’s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal date Balstilimab achieved trial endpoints with 20% response rates in PD-L1 positive patients, versus 14% reported in pembrolizumab’s label; Agenus

btn News

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

btn Stock